Komori
Business alliance4571Nano Holdings,Inc.Pharmaceuticals

Fund operated by our investment subsidiary invests in Natius Co., Ltd., "Bio Bridge I"

Through the "Bio Bridge I" fund operated by the Company's investment subsidiary NBI, the Company invested in 株式会社ナティアス, which has nucleic acid synthesis technology. The investment amount is undisclosed.

Worth reading
35Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Agreements reached under this partnership

4571Nano Holdings,Inc.
Alliance partner株式会社ナティアス
Capital and personnel relationships

This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).

Acquisition priceInvestment amount undisclosed
About the partner
Business DescriptionManufacture and sale of nucleic acid active pharmaceutical ingredients and other products based on long-chain nucleic acid synthesis technology
LocationKobe, Hyogo Prefecture
Agreements reached under this partnership
ItemDetails
Name of alliance partner株式会社ナティアス
Alliance partner's business activitiesManufacture and sale of nucleic acid active pharmaceutical ingredients and other products based on long-chain nucleic acid synthesis technology
Alliance partner's locationKobe, Hyogo Prefecture
Acquisition priceInvestment amount undisclosed
Items this document does not state (19)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceDetails of the allianceNumber of shares acquiredShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company determined that 株式会社ナティアス has strong global competitive advantages in its proprietary "Blockmer®" technology and a track record of being selected for national projects and other initiatives, and that the company has a high degree of compatibility with the Group's Gateway model, which aims to enhance corporate value by connecting outstanding Japanese technologies with overseas capital and global networks.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Fund operated by our investment subsidiary invests in Natius Co., Ltd., "Bio Bridge I" | Nano Holdings,Inc. (4571) timely disclosure | Komori